203 related articles for article (PubMed ID: 30949707)
1. Pharmacokinetics/pharmacodynamics of lefamulin in a neutropenic murine pneumonia model with Staphylococcus aureus and Streptococcus pneumoniae.
Wicha WW; Strickmann DB; Paukner S
J Antimicrob Chemother; 2019 Apr; 74(Suppl 3):iii11-iii18. PubMed ID: 30949707
[TBL] [Abstract][Full Text] [Related]
2. In vivo pharmacodynamics of lefamulin, the first systemic pleuromutilin for human use, in a neutropenic murine thigh infection model.
Wicha WW; Craig WA; Andes D
J Antimicrob Chemother; 2019 Apr; 74(Suppl 3):iii5-iii10. PubMed ID: 30949706
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetic/pharmacodynamic target attainment analyses to support intravenous and oral lefamulin dose selection for the treatment of patients with community-acquired bacterial pneumonia.
Bhavnani SM; Zhang L; Hammel JP; Rubino CM; Bader JC; Sader HS; Gelone SP; Wicha WW; Ambrose PG
J Antimicrob Chemother; 2019 Apr; 74(Suppl 3):iii35-iii41. PubMed ID: 30949705
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetic/Pharmacodynamic Evaluation of a Novel Aminomethylcycline Antibiotic, KBP-7072, in the Neutropenic Murine Pneumonia Model against Staphylococcus aureus and Streptococcus pneumoniae.
Lepak AJ; Zhao M; Liu Q; Wang P; Wang Y; Bader JC; Ambrose PG; Andes DR
Antimicrob Agents Chemother; 2019 Mar; 63(3):. PubMed ID: 30559140
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetic-Pharmacodynamic Evaluation of Gepotidacin against Gram-Positive Organisms Using Data from Murine Infection Models.
Bulik CC; Okusanya ÓO; Lakota EA; Forrest A; Bhavnani SM; Hoover JL; Andes DR; Ambrose PG
Antimicrob Agents Chemother; 2017 Feb; 61(2):. PubMed ID: 27872075
[TBL] [Abstract][Full Text] [Related]
6. Comparative In Vivo Efficacies of Tedizolid in Neutropenic versus Immunocompetent Murine Streptococcus pneumoniae Lung Infection Models.
Abdelraouf K; Nicolau DP
Antimicrob Agents Chemother; 2017 Jan; 61(1):. PubMed ID: 27799200
[TBL] [Abstract][Full Text] [Related]
7. Low Prevalence of Gram-Positive Isolates Showing Elevated Lefamulin MIC Results during the SENTRY Surveillance Program for 2015-2016 and Characterization of Resistance Mechanisms.
Mendes RE; Paukner S; Doyle TB; Gelone SP; Flamm RK; Sader HS
Antimicrob Agents Chemother; 2019 Apr; 63(4):. PubMed ID: 30670418
[TBL] [Abstract][Full Text] [Related]
8. Antibacterial Activity of Lefamulin against Pathogens Most Commonly Causing Community-Acquired Bacterial Pneumonia: SENTRY Antimicrobial Surveillance Program (2015-2016).
Paukner S; Gelone SP; Arends SJR; Flamm RK; Sader HS
Antimicrob Agents Chemother; 2019 Apr; 63(4):. PubMed ID: 30670415
[TBL] [Abstract][Full Text] [Related]
9. Lefamulin: A Novel Oral and Intravenous Pleuromutilin for the Treatment of Community-Acquired Bacterial Pneumonia.
Zhanel GG; Deng C; Zelenitsky S; Lawrence CK; Adam HJ; Golden A; Berry L; Schweizer F; Zhanel MA; Irfan N; Bay D; Lagacé-Wiens P; Walkty A; Mandell L; Lynch JP; Karlowsky JA
Drugs; 2021 Feb; 81(2):233-256. PubMed ID: 33247830
[TBL] [Abstract][Full Text] [Related]
10. Lefamulin: Review of a Promising Novel Pleuromutilin Antibiotic.
Veve MP; Wagner JL
Pharmacotherapy; 2018 Sep; 38(9):935-946. PubMed ID: 30019769
[TBL] [Abstract][Full Text] [Related]
11. In Vivo Pharmacodynamic Target Investigation of Two Bacterial Topoisomerase Inhibitors, ACT-387042 and ACT-292706, in the Neutropenic Murine Thigh Model against Streptococcus pneumoniae and Staphylococcus aureus.
Lepak AJ; Seiler P; Surivet JP; Ritz D; Kohl C; Andes DR
Antimicrob Agents Chemother; 2016 Jun; 60(6):3626-32. PubMed ID: 27044547
[TBL] [Abstract][Full Text] [Related]
12. Lefamulin: The First Systemic Pleuromutilin Antibiotic.
Chahine EB; Sucher AJ
Ann Pharmacother; 2020 Dec; 54(12):1203-1214. PubMed ID: 32493034
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetics/Pharmacodynamics of Peptide Deformylase Inhibitor GSK1322322 against Streptococcus pneumoniae, Haemophilus influenzae, and Staphylococcus aureus in Rodent Models of Infection.
Hoover J; Lewandowski T; Straub RJ; Novick SJ; DeMarsh P; Aubart K; Rittenhouse S; Zalacain M
Antimicrob Agents Chemother; 2016 Jan; 60(1):180-9. PubMed ID: 26482300
[TBL] [Abstract][Full Text] [Related]
14. Lefamulin vs moxifloxacin for community-acquired bacterial pneumonia.
Tang HJ; Wang JH; Lai CC
Medicine (Baltimore); 2020 Jul; 99(29):e21223. PubMed ID: 32702892
[TBL] [Abstract][Full Text] [Related]
15. In Vivo Pharmacodynamic Target Assessment of Delafloxacin against Staphylococcus aureus, Streptococcus pneumoniae, and Klebsiella pneumoniae in a Murine Lung Infection Model.
Lepak AJ; Andes DR
Antimicrob Agents Chemother; 2016 Aug; 60(8):4764-9. PubMed ID: 27216072
[TBL] [Abstract][Full Text] [Related]
16. 7-Year (2015-21) longitudinal surveillance of lefamulin in vitro activity against bacterial pathogens collected worldwide from patients with respiratory tract infections including pneumonia and characterization of resistance mechanisms.
Paukner S; Mendes RE; Arends SJR; Gassner G; Gelone SP; Sader HS
J Antimicrob Chemother; 2024 Feb; 79(2):360-369. PubMed ID: 38113528
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetic/Pharmacodynamic Evaluation of Solithromycin against Streptococcus pneumoniae Using Data from a Neutropenic Murine Lung Infection Model.
Okusanya OO; Forrest A; Bhavnani SM; Fernandes P; Ambrose PG; Andes DR
Antimicrob Agents Chemother; 2019 Aug; 63(8):. PubMed ID: 31182534
[TBL] [Abstract][Full Text] [Related]
18. Prediction of lefamulin epithelial lining fluid penetration after intravenous and oral administration using Phase 1 data and population pharmacokinetics methods.
Zhang L; Wicha WW; Bhavnani SM; Rubino CM
J Antimicrob Chemother; 2019 Apr; 74(Suppl 3):iii27-iii34. PubMed ID: 30949708
[TBL] [Abstract][Full Text] [Related]
19. Introduction: lefamulin and pharmacokinetic/pharmacodynamic rationale to support the dose selection of lefamulin.
Rodvold KA
J Antimicrob Chemother; 2019 Apr; 74(Suppl 3):iii2-iii4. PubMed ID: 30949709
[TBL] [Abstract][Full Text] [Related]
20. An overview of lefamulin for the treatment of community acquired bacterial pneumonia.
Falcó V; Burgos J; Almirante B
Expert Opin Pharmacother; 2020 Apr; 21(6):629-636. PubMed ID: 31958020
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
